Navigation Links
Neurobiological Technologies Reports Second Quarter Fiscal 2009 Financial Results
Date:2/12/2009

and classified as long-term investments. Total liabilities, excluding deferred revenue of $16.0 million, were $8.5 million at December 31, 2008.

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc. is a biopharmaceutical company historically focused on developing novel, first-in-class agents for central nervous system conditions and other serious unmet medical needs. The company recently terminated development of its most advanced product candidate, Viprinex(TM) (ancrod), which was studied in Phase 3 clinical trials for evaluation as a new drug to treat acute ischemic stroke. NTI has an early-stage development program for Alzheimer's disease and rights to receive payments on an approved drug for Alzheimer's disease and an investigational drug which has recently completed a Phase 3 trial for brain swelling.

NOTE: Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including risks relating to our terminated clinical trials and our continuing contractual commitments, and levels of future operations and expenditures, as well as other risks detailed from time to time in our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release and we undertake no obligation to update these forward-looking statements.




                         CONDENSED STATEMENTS OF OPERATIONS
               (Unaudited - in thousands, except per share amounts)


                                    Three months ended   Six months ended
                                        December 31,        Decem
'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
2. Neurobiological Technologies Announces Suspension of Viprinex Development
3. Neurobiological Technologies Partner, Celtic Pharma, Provides Update on XERECEPT(R) Clinical Program and Planned Sale in 2009
4. Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results
5. Neurobiological Technologies to Present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York on November 10
6. Neurobiological Technologies Sets Date for First Quarter Financial Results
7. Neurobiological Technologies Reports Receipt of $2 Million Royalty Payment for Quarterly Sales of Memantine
8. Neurobiological Technologies to Present at the BIO Investor Forum in San Francisco on October 30, 2008
9. Neurobiological Technologies Announces Update Call on Viprinex (TM) Phase 3 Trial Program
10. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q4/08 Review Issued by Scimitar Equity, LLC
11. Neurobiological Technologies Announces Dates for 2008 Fiscal Year End Financial Results Conference Call and Presentation at MCF Investor Summit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 23, 2014 China Biologic Products, Inc. ... leading fully integrated plasma-based biopharmaceutical company in ... majority-owned subsidiary, Shandong Taibang Biological Products Co. Ltd., ... the China Food and Drug Administration (the "CFDA") ... previously disclosed in the Company,s public filings, the ...
(Date:12/24/2014)... SARASOTA, Fla. , Dec. 23, 2014  Rock ... today that it has filed a Clinical Trial Application ... Medicines Healthcare products Regulatory Agency (MHRA) seeking regulatory approval ... its lead molecule, Anatabine Citrate. Contingent on ... to conduct a Phase I trial to assess the ...
(Date:12/22/2014)... - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), ... development of autologous cell therapies, announced today the publication ... in conjunction with co-authors from Kyoto University and the ... ongoing clinical research using dermal sheath cup (DSC) cells ... The paper entitled " Hair Follicle Dermal Stem Cells ...
(Date:12/22/2014)... The American Journal of ... research, reviews and editorials addressing developments and pathways ... published a provocative article exploring the role of ... potential treatment of prostate cancer. , The ... the possibility that there could be a connection ...
Breaking Biology Technology:China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4
... Placing the lower case "i" next to a word as a ... fame and glory may be possible, the chances of creating a ... icon is the exclusive longevity of its unique name, and for ... iWatch, Panasonic and not iTV. , ,Terms like interactive ...
... annual outlook for the year in a renovated Grand Ballroom of ... Froehlich of Deutsche Asset Management , Allan Murray of the ... Financial . , , Chicago Sun-Times columnist Terry Savage moderated ... spotlight on. , , Comparing last year to this year ...
... - The Medical College of Wisconsin , in ... been awarded a five-year, $8.1 million federal grant to develop ... and the majority of potential bioterrorism agents. , ,The grant, ... Institute of Allergy and Infectious Diseases , will be used ...
Cached Biology Technology:The I of the storm: iPhones, iPains, and iProblems 2The I of the storm: iPhones, iPains, and iProblems 3The I of the storm: iPhones, iPains, and iProblems 4Economic outlook for 2007, and still clueless on Apple 2Economic outlook for 2007, and still clueless on Apple 3Economic outlook for 2007, and still clueless on Apple 4Economic outlook for 2007, and still clueless on Apple 5Medical College lands $8.1M grant to detect bird flu, bioterror agents 2
(Date:12/10/2014)... 2014 You,ve been here before: you desperately need ... your password, site key or the answer to your secret ... teacher? Today, Hoyos Labs , a ... will finally put an end to the frustration that comes ... . 1U leverages a user,s smartphone to acquire his or ...
(Date:12/10/2014)... , Dec. 08, 2014 Research and Markets ... addition of the "Biometrics Market in Japan ... http://photos.prnewswire.com/prnh/20130307/600769 The ... such as rural banking and upgradation of the ... witnessed in the market. Besides the aforementioned projects, ...
(Date:12/4/2014)... , Dec. 3, 2014  Crossmatch™, a ... announced that its DigitalPersona ® Pro Enterprise ... have been deployed throughout First Bank branch locations ... South Carolina and Virginia. First Bank, ... Southern Pines, North Carolina , selected ...
Breaking Biology News(10 mins):The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
... is funding a new Physics Frontiers Center at the University ... Living Cells is one of nine Physics Frontiers Centers in ... biological systems. The $7.5 million award will be supplemented ... the total funding to $8.25 million over five years. ...
... that contains enough essential vitamins and minerals. Analysis ... status has shown that the average child gets the recommended ... more added sugars than recommended. The study published ... at a nationally representative sample of children aged 4-18 years ...
... available in German . , Dessau. Extreme ... more than plants. This is the finding of a study ... TU Berlin, the German Federal Institute of Hydrology (BfG), KON ... before and after the Elbe floods of August 2002. Flow ...
Cached Biology News:NSF funds new 'Center for the Physics of Living Cells' at Illinois 2NSF funds new 'Center for the Physics of Living Cells' at Illinois 3Variety of foods -- the key for child nutrition 2Vegetation hardly affected by extreme flood events 2
... 820-MS features Varians unique collision reaction ... routine removal of troublesome spectroscopic interferences. ... interference-free analysis without the worry of ... guides, or cells. And, by coupling ...
... enables scientists who have access to microarray scanning ... printed with proteins from S&Ss antibody menu or ... is performed by the customer. Its as easy ... needs with an expert and define the best ...
a1-Antitrypsin (human, alpha-1 AT)...
... quadrupole 1200L sets the new standard ... - incorporating the latest technologies and ... chromatography analytical needs. The Atmospheric ... Transmission Quadrupole Analyzer provide superior selectivity ...
Biology Products: